Featured
-
-
Article
| Open Access
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
In a phase 1 dose-escalation trial in patients with nine different types of solid tumors, MAGE-A4-specific T cells had an acceptable safety profile and exhibited an encouraging overall response rate in patients with synovial sarcoma.
- David S. Hong
- , Brian A. Van Tine
- & Marcus O. Butler
-
Article |
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
In a trial of patients with soft-tissue sarcomas, clinical outcome measures following anti-PD-1 treatment were better in a cohort prospectively selected for the presence of intratumoral tertiary lymphoid structures than in other cohorts where most patients lacked these structures.
- A. Italiano
- , A. Bessede
- & W. H. Fridman
-
Article |
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
The combination of anti-GD2 and CD47 blockade mediates robust anti-tumor activity in mouse models of neuroblastoma, osteosarcoma and small-cell lung cancer by reorienting macrophage activity toward tumor cell phagocytosis.
- Johanna Theruvath
- , Marie Menard
- & Robbie G. Majzner
-
Article |
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Single-cell transcriptional profiling of primary human synovial sarcoma tumors suggests that combinatorial treatment with HDAC and CDK4/CDK6 inhibitors could enhance tumor immunogenicity.
- Livnat Jerby-Arnon
- , Cyril Neftel
- & Aviv Regev
-
Letter |
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research
A framework of patient-partnered research allows patients with angiosarcoma to share their samples and clinical records securely to accelerate molecular characterization of tumors and identification of therapeutic approaches.
- Corrie A. Painter
- , Esha Jain
- & Nikhil Wagle
-
Article |
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
Peter Scacheri and colleagues report that the activity of enhancer elements in metastatic osteosarcoma is distinct from that in primary tumors and plays a functional role in metastatic progression of osteosarcoma.
- James J Morrow
- , Ian Bayles
- & Peter C Scacheri
-
News & Views |
Ephrin receptor: a door to KSHV infection
Kaposi's sarcoma–associated herpesvirus is a major oncogenic virus that has been implicated in human cancers. A new study identifies ephrin receptor A2 as a key host receptor for this virus that permits infection of endothelial cells (pages 961–966).
- Chris Boshoff
-
Letter |
The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus
Kaposi's sarcoma–associated herpesvirus (KSHV) can infect endothelial cells, leading to the development of Kaposi's sarcoma in some individuals. The mechanisms underlying cell entry by KSHV are not fully elucidated. ahn et al. now report that ephrin receptor tyrosine kinase A2 (EphA2) acts as a cellular receptor for KSHV and show that blocking EphA2 inhibits infection of endothelial cells.
- Alexander S Hahn
- , Johanna K Kaufmann
- & Frank Neipel
-
Article |
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
A prognostic gene expression signature predicts metastasis in individuals with sarcomas and other tumor types more accurately than existing tools.
- Frédéric Chibon
- , Pauline Lagarde
- & Alain Aurias
-
Between Bedside and Bench |
Muscling in: Gene therapies for muscular dystrophy target RNA
Muscle diseases can take many forms, from the progressive muscle degeneration of dystrophies to the childhood cancer rhabdomyosarcoma. In 'Bench to Bedside', Joel R. Chamberlain and Jeffrey S. Chamberlain discuss studies using antisense oligonucleotides to treat Duchenne muscular dystrophy and myotonic dystrophy. In 'Bedside to Bench', Simone Hettmer and Amy J. Wagers examine the implications of clinical studies describing a type of rhabdomyosarcoma that resembles acute leukemia. The findings dovetail with other studies suggesting that some of these cancers might originate outside of muscle tissue and highlight the need for a better understanding of the cells that give rise to this condition.
- Joel R Chamberlain
- & Jeffrey S Chamberlain
-
Between Bedside and Bench |
Muscling in: Uncovering the origins of rhabdomyosarcoma
- Simone Hettmer
- & Amy J Wagers
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial